Endo International

Endo International plc
Company type	Public
Traded as	Expert Market: ENDPQ; Nasdaq: ENDP;
ISIN	IE00BJ3V9050
Industry	Pharmaceutical
Predecessor	Endo Pharmaceuticals Inc. (before the 2014 tax inversion to Ireland)
Founded	1997
Headquarters	(Legal) Dublin, Ireland; (Operational) Malvern, Pennsylvania, United States.;
Key people	Paul Campanelli (CEO); Blaise Coleman (CFO);
Revenue	US$2,993 million (2021); US$2,903 million (2020);
Operating income	US$−547 million (2021); US$−27 million (2020);
Net income	US$−613 million (2021); US$184 million (2020);
Total assets	US$2,715 million (2021); US$2,413 million (2020);
Number of employees	3103 (2021)
Website	endo.com
	Footnotes / references; Financials

Endo International plc is an American Irish-domiciled generics and specialty branded pharmaceutical company that generated over 93% of its 2017 sales from the U.S. healthcare system. While Endo's management, operations, and customers are almost exclusively U.S.–based, in 2013 Endo executed a corporate tax inversion to Ireland to avoid U.S. corporate taxes on their U.S. drug sales, and to avail of Ireland's corporate tax system.

Endo net sales by region (2017)
Region	Sales ($ m)	Distribution (%)
U.S. Generic	2,281.0	65.8
U.S. Branded	957.5	27.6
Non-U.S. / International	230.3	6.6
Total	3,468.8	100.0